Vimarsana
Biggest News Aggregation in the World

Bio Abecma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bio Abecma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bio Abecma Today - Breaking & Trending Today

FDA Greenlights BMS, J&J CAR-T Therapies for Earlier Multiple Myeloma Treatment - Vimarsana News

FDA Greenlights BMS, J&J CAR-T Therapies for Earlier Multiple Myeloma Treatment

Published: April 6, 2024

The approvals, third line for BMS and 2seventy Bio’s Abecma and second line for J&J and Legend Biotech’s Carvykti, represent a new class of therapy for these blood cancer patients.

Source: biospace.com
Related Topics:
United StatesSan DiegoBio AbecmaBryan CampbellEuropean CommissionOncologic Drugs Advisory CommitteeBristol Myers SquibbNicole BeanLegend BiotechDrugs Advisory CommitteeEuropean Medicines AgencyMedicinal ProductsHuman UseDa Greenlights BmsJ Ampj Cart Therapies For Earlier Multiple Myeloma Treatment
ASH23: Pharma branding, Editas' high bar and clinical trial diversity - Vimarsana News

ASH23: Pharma branding, Editas' high bar and clinical trial diversity

Published: December 12, 2023

BioPharma

Source: biopharmadive.com
Related Topics:
United StatesSaad UsmaniCaren DeardorfGwendolyn Wu BiopharmaNicole VerdunJohnson TecvayliBaisong MeiNicole GormleyBio AbecmaPunam MalikVertex PharmaceuticalsInternational Myeloma FoundationMemorial Sloan Kettering Cancer CenterDrug AdministrationBristol Myers SquibbAmerican Society Of HematologyAmerican SocietyNative AmericanInternational MyelomaLegend BiotechMemorial Sloan Kettering CancerDrug Omnibus Reform ActEditas MedicineCincinnati ChildrenClinical Trials
5 FDA decisions to watch in the fourth quarter - Vimarsana News

5 FDA decisions to watch in the fourth quarter

Published: October 2, 2023

BioPharma

Source: biopharmadive.com
Related Topics:
Ned PagliaruloBio AbecmaJonathan GardnerBristol Myer ZeposiaAmgen LumakrasStifel Paul MatteisAlnylam OnpattroBristol MyersAlnylam PharmaceuticalsDrug AdministrationArena PharmaceuticalsBristol Myers SquibbVertex PharmaceuticalsWall StreetPaul MatteisMyers SquibbLegend Biotech
FDA approves bispecific drug from Pfizer for multiple myeloma - Vimarsana News

FDA approves bispecific drug from Pfizer for multiple myeloma

Published: August 14, 2023

BioPharma

Source: biopharmadive.com
Related Topics:
Bio AbecmaBristol Myers SquibbDrug Administration OnDive BriefDrug AdministrationLegend Biotech
Legend Biotech: Label Expansions Necessary To Realize Carvykti's Potential (NASDAQ:LEGN) - Vimarsana News

Legend Biotech: Label Expansions Necessary To Realize Carvykti's Potential (NASDAQ:LEGN)

Published: October 28, 2022

Legend Biotech's Carvykti has been approved and is selling well despite manufacturing issues. Analysts have set multibillion target peak sales for the product. Read more here.

Source: seekingalpha.com
Related Topics:
New YorkUnited StatesNew York Stock ExchangeBio AbecmaYork Stock ExchangeLegend Biotech CorporationErnst YoungBristol Myers SquibbPublic Company Accounting Oversight BoardBiotech CorporationCytokine Release SyndromeMacrophage Activation SyndromeRisk EvaluationMitigation Strategy